Sartorius Stedim Biotech SA 2008 IR
The report outlines the financial and operational performance of the Sartorius Stedim Biotech Group for the fiscal year 2008. Despite challenging market conditions in North America, the Group achieved sales revenue of ’368.0 million and maintained a robust EBITA margin of 10.9%. Key milestones included the successful completion of the integration of the Sartorius Biotechnology Division and Stedim, the acquisition of Wave Biotech AG, and the expansion of sales networks in Hungary and Poland. On the environmental front, the company invested ’1.8 million in projects at its Goettingen site, including a new combined heat and power plant that reduces CO2 emissions by 2,500 metric tons annually, and a solvent recycling facility.
Company: Sartorius Stedim Biotech SA
Sector: Manufacturing
Country: France
Year: 2008
Type: IR
Pages: 181
Back to company
Sartorius Stedim Biotech SA
Reference Document
The report outlines the financial and operational performance of the Sartorius Stedim Biotech Group for the fiscal year 2008. Despite challenging market conditions in North America, the Group achieved sales revenue of ’368.0 million and maintained a robust EBITA margin of 10.9%. Key milestones included the successful completion of the integration of the Sartorius Biotechnology Division and Stedim, the acquisition of Wave Biotech AG, and the expansion of sales networks in Hungary and Poland. On the environmental front, the company invested ’1.8 million in projects at its Goettingen site, including a new combined heat and power plant that reduces CO2 emissions by 2,500 metric tons annually, and a solvent recycling facility.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2008
Reporting Period
Jan 1, 2008 - Dec 31, 2008
Fiscal Year
2008
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees